340 related articles for article (PubMed ID: 32686686)
1. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival.
Zaidi SH; Harrison TA; Phipps AI; Steinfelder R; Trinh QM; Qu C; Banbury BL; Georgeson P; Grasso CS; Giannakis M; Adams JB; Alwers E; Amitay EL; Barfield RT; Berndt SI; Borozan I; Brenner H; Brezina S; Buchanan DD; Cao Y; Chan AT; Chang-Claude J; Connolly CM; Drew DA; Farris AB; Figueiredo JC; French AJ; Fuchs CS; Garraway LA; Gruber S; Guinter MA; Hamilton SR; Harlid S; Heisler LE; Hidaka A; Hopper JL; Huang WY; Huyghe JR; Jenkins MA; Krzyzanowski PM; Lemire M; Lin Y; Luo X; Mardis ER; McPherson JD; Miller JK; Moreno V; Mu XJ; Nishihara R; Papadopoulos N; Pasternack D; Quist MJ; Rafikova A; Reid EEG; Shinbrot E; Shirts BH; Stein LD; Teney CD; Timms L; Um CY; Van Guelpen B; Van Tassel M; Wang X; Wheeler DA; Yung CK; Hsu L; Ogino S; Gsur A; Newcomb PA; Gallinger S; Hoffmeister M; Campbell PT; Thibodeau SN; Sun W; Hudson TJ; Peters U
Nat Commun; 2020 Jul; 11(1):3644. PubMed ID: 32686686
[TBL] [Abstract][Full Text] [Related]
2. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
[TBL] [Abstract][Full Text] [Related]
3. Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer.
Suzuki Y; Ng SB; Chua C; Leow WQ; Chng J; Liu SY; Ramnarayanan K; Gan A; Ho DL; Ten R; Su Y; Lezhava A; Lai JH; Koh D; Lim KH; Tan P; Rozen SG; Tan IB
Mol Oncol; 2017 Feb; 11(2):124-139. PubMed ID: 28145097
[TBL] [Abstract][Full Text] [Related]
4. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
5.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
7. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
8. p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Oh HJ; Bae JM; Wen X; Jung S; Kim Y; Kim KJ; Cho NY; Kim JH; Han SW; Kim TY; Kang GH
Br J Cancer; 2019 Apr; 120(8):797-805. PubMed ID: 30894685
[TBL] [Abstract][Full Text] [Related]
9. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
10. Novel DNA variants and mutation frequencies of hMLH1 and hMSH2 genes in colorectal cancer in the Northeast China population.
Hu F; Li D; Wang Y; Yao X; Zhang W; Liang J; Lin C; Ren J; Zhu L; Wu Z; Li S; Li Y; Zhao X; Cui B; Dong X; Tian S; Zhao Y
PLoS One; 2013; 8(4):e60233. PubMed ID: 23573243
[TBL] [Abstract][Full Text] [Related]
11. Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.
Reynolds IS; O'Connell E; Fichtner M; McNamara DA; Kay EW; Prehn JHM; Furney SJ; Burke JP
J Surg Oncol; 2019 Dec; 120(8):1427-1435. PubMed ID: 31729037
[TBL] [Abstract][Full Text] [Related]
12. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer.
Naccarati A; Polakova V; Pardini B; Vodickova L; Hemminki K; Kumar R; Vodicka P
Mutagenesis; 2012 Mar; 27(2):211-8. PubMed ID: 22294769
[TBL] [Abstract][Full Text] [Related]
13. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
[TBL] [Abstract][Full Text] [Related]
15. TP53 somatic mutations are associated with somatic mitogenome substitutions but not indels in colorectal cancer cells.
Skonieczna K; Jawień A; Marszałek A; Grzybowski T
J Gene Med; 2019 Jan; 21(1):e3063. PubMed ID: 30548163
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer.
Kim JE; Choi J; Sung CO; Hong YS; Kim SY; Lee H; Kim TW; Kim JI
Exp Mol Med; 2021 Mar; 53(3):446-456. PubMed ID: 33753878
[TBL] [Abstract][Full Text] [Related]
17. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.
Dallol A; Buhmeida A; Al-Ahwal MS; Al-Maghrabi J; Bajouh O; Al-Khayyat S; Alam R; Abusanad A; Turki R; Elaimi A; Alhadrami HA; Abuzenadah M; Banni H; Al-Qahtani MH; Abuzenadah AM
J Transl Med; 2016 May; 14(1):118. PubMed ID: 27146902
[TBL] [Abstract][Full Text] [Related]
19. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
20. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients.
Hassin O; Nataraj NB; Shreberk-Shaked M; Aylon Y; Yaeger R; Fontemaggi G; Mukherjee S; Maddalena M; Avioz A; Iancu O; Mallel G; Gershoni A; Grosheva I; Feldmesser E; Ben-Dor S; Golani O; Hendel A; Blandino G; Kelsen D; Yarden Y; Oren M
Nat Commun; 2022 May; 13(1):2800. PubMed ID: 35589715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
